Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer

A phase II study

M. Javle, J. Yu, C. Garrett, A. Pande, B. Kuvshinoff, Alan Litwin, J. Phelan, J. Gibbs, R. Iyer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

Original languageEnglish (US)
Pages (from-to)1842-1845
Number of pages4
JournalBritish Journal of Cancer
Volume100
Issue number12
DOIs
StatePublished - Jun 16 2009

Fingerprint

gemcitabine
Pancreatic Neoplasms
Disease-Free Survival
Hemorrhage
Hypertension
Survival
Bevacizumab
Capecitabine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Javle, M., Yu, J., Garrett, C., Pande, A., Kuvshinoff, B., Litwin, A., ... Iyer, R. (2009). Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study. British Journal of Cancer, 100(12), 1842-1845. https://doi.org/10.1038/sj.bjc.6605099
Javle, M. ; Yu, J. ; Garrett, C. ; Pande, A. ; Kuvshinoff, B. ; Litwin, Alan ; Phelan, J. ; Gibbs, J. ; Iyer, R. / Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer : A phase II study. In: British Journal of Cancer. 2009 ; Vol. 100, No. 12. pp. 1842-1845.
@article{9cfebb4ab655490bacc100d8bbce0037,
title = "Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study",
abstract = "A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).",
author = "M. Javle and J. Yu and C. Garrett and A. Pande and B. Kuvshinoff and Alan Litwin and J. Phelan and J. Gibbs and R. Iyer",
year = "2009",
month = "6",
day = "16",
doi = "10.1038/sj.bjc.6605099",
language = "English (US)",
volume = "100",
pages = "1842--1845",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

Javle, M, Yu, J, Garrett, C, Pande, A, Kuvshinoff, B, Litwin, A, Phelan, J, Gibbs, J & Iyer, R 2009, 'Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study', British Journal of Cancer, vol. 100, no. 12, pp. 1842-1845. https://doi.org/10.1038/sj.bjc.6605099

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer : A phase II study. / Javle, M.; Yu, J.; Garrett, C.; Pande, A.; Kuvshinoff, B.; Litwin, Alan; Phelan, J.; Gibbs, J.; Iyer, R.

In: British Journal of Cancer, Vol. 100, No. 12, 16.06.2009, p. 1842-1845.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer

T2 - A phase II study

AU - Javle, M.

AU - Yu, J.

AU - Garrett, C.

AU - Pande, A.

AU - Kuvshinoff, B.

AU - Litwin, Alan

AU - Phelan, J.

AU - Gibbs, J.

AU - Iyer, R.

PY - 2009/6/16

Y1 - 2009/6/16

N2 - A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

AB - A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

UR - http://www.scopus.com/inward/record.url?scp=67349250514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349250514&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605099

DO - 10.1038/sj.bjc.6605099

M3 - Article

VL - 100

SP - 1842

EP - 1845

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -